GNH USA

Europe — EMA

Metformina + Vildagliptina Generis (Metformin Hydrochloride, Vildagliptin)

GNH USA supplies Metformina + Vildagliptina Generis (Metformin Hydrochloride and Vildagliptin), an antidiabetic for type 2 diabetes.

Metformin Hydrochloride, Vildagliptin

Request sourcing

1
Pack/s

What is Metformin Hydrochloride, Vildagliptin?

Metformin Hydrochloride and Vildagliptin, the active ingredient in Metformina + Vildagliptina Generis, is a biguanide and DPP‑4 inhibitor presented as a strength/form not specified for oral use. It is used to improve glycemic control in adults with type 2 diabetes mellitus.

GNH USA supplies Metformina + Vildagliptina Generis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

What is Metformin Hydrochloride, Vildagliptin used for?

Metformina + Vildagliptina Generis combines metformin and vildagliptin to address hyperglycemia in type 2 diabetes.

- Type 2 diabetes mellitus: lowers fasting and post‑prandial blood glucose levels. - Adjunct to diet and exercise: enhances overall glycaemic control when lifestyle measures are insufficient. - Combination with insulin therapy: provides additional glucose lowering in patients requiring insulin.

What are the side effects of Metformin Hydrochloride, Vildagliptin?

The following adverse reactions have been reported with the combination of metformin and vildagliptin.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, or dyspepsia. - Diarrhoea: loose stools occurring especially after treatment initiation. - Headache: mild to moderate intensity. - Metallic taste: transient alteration in taste perception.

Serious or Rare Side Effects: - Lactic acidosis: a rare but life‑threatening metabolic complication. - Pancreatitis: inflammation of the pancreas presenting with severe abdominal pain. - Severe hypersensitivity reactions: including skin rash, Stevens‑Johnson syndrome, or anaphylaxis.

What precautions apply to Metformin Hydrochloride, Vildagliptin?

When prescribing Metformina + Vildagliptina Generis, clinicians should consider several safety aspects.

- Renal function: assess eGFR before initiation and monitor periodically. - Hepatic impairment: use with caution in patients with liver disease. - Risk of lactic acidosis: avoid in conditions predisposing to hypoxia or severe infection. - Pregnancy and lactation: evaluate risk–benefit; limited data are available. - Drug interactions: review concomitant medications for potential interactions. - Store at ambient temperature: keep below 25 °C, protect from moisture and light in the original packaging.

What does Metformin Hydrochloride, Vildagliptin interact with?

Metformina + Vildagliptina Generis may interact with several medicines; some require avoidance while others need monitoring.

Major Interactions (Avoid): - Severe renal impairment (eGFR <30 mL/min/1.73 m²): contraindicated due to lactic acidosis risk. - Potent CYP2C9 inhibitors: may increase metformin plasma concentrations. - Co‑administration with other DPP‑4 inhibitors: duplicate therapy should be avoided.

Moderate Interactions (Monitor Closely): - Sulfonylureas or insulin: increased risk of hypoglycaemia. - Diuretics (especially thiazides): may affect renal clearance of metformin. - Excessive alcohol intake: heightens lactic acidosis risk.

Frequently asked questions

What is Metformina + Vildagliptina Generis used for?+
Metformina + Vildagliptina Generis is indicated for the treatment of type 2 diabetes mellitus in adults. It helps lower both fasting and post‑prandial blood glucose levels when used together with diet and exercise.
How does Metformin Hydrochloride work in this combination?+
Metformin Hydrochloride reduces hepatic glucose production and increases peripheral insulin sensitivity, which together decrease the amount of glucose released into the bloodstream and improve the body’s response to insulin.
What is the usual dose of Metformina + Vildagliptina Generis?+
The specific dose and dosing schedule are determined by the prescribing healthcare professional based on the patient’s clinical condition, renal function, and response to therapy. Patients should follow the prescriber’s instructions exactly.
Is Metformina + Vildagliptina Generis safe during pregnancy or breastfeeding?+
Safety data in pregnancy and lactation are limited. The prescriber must weigh the potential benefits against possible risks before using this medication in pregnant or nursing women.
How do I order Metformina + Vildagliptina Generis from GNH USA?+
Enquiries can be submitted on the product page at gnh-usa.com, specifying the required quantity. GNH USA supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.
How does this product compare with other antidiabetic options?+
Metformina + Vildagliptina combines a biguanide (metformin) with a DPP‑4 inhibitor (vildagliptin), offering complementary mechanisms. Compared with metformin alone, it provides additional post‑prandial glucose control, while avoiding the need for separate DPP‑4 inhibitor tablets.
What are the storage requirements for Metformina + Vildagliptina Generis?+
Store the product at ambient temperature, preferably below 25 °C. Keep it in the original packaging, protect it from moisture and direct light, and ensure the container is tightly closed.
How is Metformina + Vildagliptina Generis administered?+
The medication is taken orally, usually with meals to reduce gastrointestinal discomfort. Tablets should be swallowed whole with a sufficient amount of water unless otherwise directed by the prescriber.
What are the most serious risks associated with this medication?+
The most serious risks include lactic acidosis, which can be life‑threatening, and pancreatitis. Patients should be educated to seek immediate medical attention if they experience severe abdominal pain, unexplained weakness, or rapid breathing.
Who should not use Metformina + Vildagliptina Generis?+
Patients with severe renal impairment (eGFR <30 mL/min/1.73 m²), known hypersensitivity to metformin or vildagliptin, or those with a history of lactic acidosis should not use this product.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Metformin Hydrochloride, Vildagliptin
Route
Oral Use
Manufacturer
Generis Farmacêutica, S.A.
Origin
EU

Related products

Agartha Duo

Agartha Duo

Metformin Hydrochloride, Vildagliptin

Gedeon Richter Plc.
EU
Agartha Duo

Agartha Duo

Metformin Hydrochloride, Vildagliptin

Gedeon Richter România S.A.
EU
Alikval Duo

Alikval Duo

Metformin Hydrochloride, Vildagliptin

Egis Pharmaceuticals Plc
EU
Alikval Duo

Alikval Duo

Metformin Hydrochloride, Vildagliptin

Egis Pharmaceuticals Plc
EU